Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIIb RB0026 injection vs placebo for RSV prevention in Chinese children aged 1–2 years
ChiCTR2600116441Phase 3Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Guangzhou Medical University
- Start
- Jan 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in respiratory syncytial virus disease (RSV), pulmonary infection and Airways Infection comparing RB0026 injection with Placebo injection (2 arms). Primary endpoint: Incidence of RT-PCR-confirmed RSV medically attended lower respiratory tract infections (MALRTI) within 150 days after dosing. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
RB0026
03
Conditions
respiratory syncytial virus disease (RSV)pulmonary infectionAirways Infection
Beyond the preview
Go deeper on ChiCTR2600116441.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600116441.